$1.41
9.62%
Nasdaq, Oct 02, 04:21 pm EDT. Closed.
ISIN
CA14161Y2006
Symbol
CRDL

Cardiol Therapeutics Inc - Ordinary Shares - Class A Stock price

$1.41
-0.76 35.02% 1M
+0.00 0.00% 6M
+0.46 47.83% YTD
+0.36 34.29% 1Y
+0.53 60.23% 3Y
-2.14 60.28% 5Y
-2.33 62.32% 10Y
-2.33 62.32% 20Y
Nasdaq, Closing price Fri, Oct 02 2026
-0.15 9.62%
ISIN
CA14161Y2006
Symbol
CRDL
Industry

Is Cardiol Therapeutics Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
$188.9m
Enterprise Value
$170.6m
Net debt
positive
Cash
$18.3m
Shares outstanding
115.9m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
negative | negative
P/B
11.2
Financial Health
Equity Ratio
75.7%
Return on Equity
-
ROCE
-148.8%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$7.9m | -
SBC as % of FCF
-
SBC Growth 1Y
-26.4%
Share Count Growth 1Y
40.2%
Shareholder Yield
-40.2%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
$-25.1m
EBIT
$-25.2m
Net Income
$-23.9m
Free Cash Flow | ex SBC
$-16.9m | $-24.8m
Growth
Revenue | estimate
- | -
EBITDA
10.5%
EBIT
10.9%
Net Income
9.3%
Free Cash Flow
4.0%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-0.2
FCF per Share
$-0.1
Short interest
2.8%
Employees
18
Rev per Employee
-

Cardiol Therapeutics Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Cardiol Therapeutics Inc - Ordinary Shares - Class A forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Cardiol Therapeutics Inc - Ordinary Shares - Class A forecast:

Buy
88%
Hold
13%

Financial data from Cardiol Therapeutics Inc - Ordinary Shares - Class A

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 14 14
21% 21%
-
- Research and Development Expense 11 11
8% 8%
-
-25 -25
10% 10%
-
- Depreciation and Amortization 0.06 0.06
70% 70%
-
EBIT (Operating Income) EBIT -25 -25
11% 11%
-
Net Profit -24 -24
9% 9%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cardiol Therapeutics Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cardiol Therapeutics Inc - Ordinary Shares - Class A Stock News

Neutral
PRNewsWire
●
11 days ago
Original 110-patient enrollment target achieved ahead of the Company's end-of-September guidance. The MAVERIC Steering Committee recommends expanding enrollment to up to 150 patients to capture sufficient events for a robust assessment of CardiolRx™'s potential to reduce recurrence risk.
Neutral
PRNewsWire
●
18 days ago
Proceeds strengthen balance sheet ahead of pivotal Phase III MAVERIC trial data readout in recurrent pericarditis and extends cash runway into H1 2028. TORONTO, Sept.
Neutral
PRNewsWire
●
23 days ago
TORONTO, Sept. 10, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has filed a preliminary short form base shelf prospectus (the "Shelf Prospectus") with the securities regulatory authorities in each of the ...
More Cardiol Therapeutics Inc - Ordinary Shares - Class A News

Company Profile

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company that focuses on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its product, CardiolRx, is a pharmaceutically produced extra strength oral cannabidiol formulation that is entering a Phase II/III outcomes study in hospitalized patients testing positive for the COVID-19 virus. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.

Head office Canada
CEO Mr. Elsley
Employees 18
Founded 2017
Website www.cardiolrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today